RESEARCH ARTICLE

Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer

Mariyam Zuberi1, Imran Khan2, Rashid Mir3, Gauri Gandhi4, Prakash Chandra Ray1, Alpana Saxena1

1 Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi, India, 2 Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, United States of America, 3 Prince Fahd Bin Sultan Research Chair, Faculty of Applied Medical Sciences, University of Tabuk, Saudi Arabia, Tabuk-71491, 4 Department of Gynaecology and Obstetrics, Lok Nayak Hospital, New Delhi, India

☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* alpanasaxena@hotmail.com

Abstract

MicroRNAs (miRNAs) have been found to be dysregulated in epithelial ovarian cancer (EOC) and may function as either tumor suppressor genes (TSGs) or as oncogenes. Hypermethylation of miRNA silences the tumour suppressive function of a miRNA or hypermethylation of a TSG regulating that miRNA (or vice versa) leads to its loss of function. The present study aims to evaluate the impact of aberrant microRNA-125b (miR-125b) expression on various clinicopathological features in epithelial ovarian cancer and its association with anomalous methylation of several TSGs. We enrolled 70 newly diagnosed cases of epithelial ovarian cancer, recorded their clinical history and 70 healthy female volunteers. Serum miR-125b levels were determined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and the methylation status of various TSGs was investigated by methylation specific PCR. ROC curves were constructed to estimate the diagnostic and prognostic usefulness of miR-125b. The expression of miR-125b was found to be significantly upregulated (p<0.0001) in comparison with healthy controls. The expression level of miR-125b was found to be significantly associated with FIGO stage, lymph node and distant metastasis. ROC curve for diagnostic potential yielded significant AUC with an equitable sensitivity and specificity. ROC curves for prognosis yielded significant AUCs for histological grade, distal metastasis, lymph node status and survival. The expression of miR-125b also correlated significantly with the hypermethylation of TSGs. Our results indicate that DNA hypermethylation may be involved in the inactivation of miR-125b and miR-125b may function as a potential independent biomarker for clinical outcome in EOC.
Introduction
Ovarian cancer is the leading cause of cancer-related deaths worldwide. The high rate of mortality may be due to difficulties in diagnosing it at an early stage and lack of effective treatments for patients with an advanced or recurrent disease[1]. Therefore, there is a critical prerequisite for developing prognostic and predictive markers to detect it early and to help optimize treatment.

MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that could induce post-transcriptional silencing of target genes by interacting with their 3'-UTR (untranslated region), thus regulating many important biological processes such as cell development, differentiation and apoptosis[2]. Taking into account the important regulatory roles miRNA play in cancer development and progression, several studies have been conducted to identify miRNA as potential biomarkers for cancer diagnosis, prognosis and personalized therapy[3].

Aberrant miRNA expression has been frequently observed in various types of human tumors. Studies suggest that miRNAs may function as either tumor-suppressor genes (TSGs) or oncogenes[4]. Recent studies reported dysregulation of miR-125b in various cancers[5,6]. However, the mechanism by which miR-125b contributes to epithelial ovarian cancer (EOC) has not been documented and is still relatively unclear. High expression of miR-125 had been observed in gliomas and prostate cancer[7,8] while miR-125 levels were seen to decrease in breast and gastric cancer[9,10]. To date, the expression level of miR-125b in epithelial ovarian cancer is not clear yet. As per the putative promoter region, the promoter of miR-125b is embedded in CpG island[11].

Considering the above findings, we tested the expression of miR-125b in serum of epithelial ovarian cancer patients to elucidate its utility as a diagnostic/prognostic marker. We also analysed the methylation pattern in a panel of tumour suppressor genes such as DAPK1, p16, RASSF1A, PTEN, BRCA1 and p14 and explored its association with the aberrant expression of miR-125b.

Materials and Methods

Patient Samples
Blood samples were procured from clinically diagnosed epithelial ovarian cancer patients. The patients (n = 70) were recruited from the Department of Gynaecology and Obstetrics, Lok Nayak Hospital, New Delhi between June 2012 and October 2014. Equal number (n = 70) of female volunteers (age matched) served as controls. Serum was separated by centrifugation. All samples were collected and stored at -70°C and thawed immediately before assay. Complete clinical data and current therapy plan was obtained. The purpose of the sampling was explained to all patients and written informed consent was obtained prior to enrolment. The study was approved by the Institutional Ethics Committee at Maulana Azad Medical College, New Delhi, India.

DNA Extraction
Genomic DNA was isolated from blood specimens of patients and controls by using the Geneaid DNA Isolation Kit (Taiwan) in accordance with the manufacturer's instructions. The quality and integrity of DNA from these tissues were checked by electrophoresis on 1% agarose gel, quantified spectrophotometrically, and then stored at -20°C for further use.

Bisulfite Modification of DNA
Bisulfite treatment was carried out using the BisulFlash DNA Modification Kit (Epigentek, USA) according to the manufacturer's guidelines. This procedure modifies unmethylated
cytosines to uracil nucleotides but does not modify methylated cytosine nucleotides. Bisulphite conversion of DNA was carried out at 95°C for 20 minutes during which unmethylated cytosines were converted into uracil completely. This was followed by the converted DNA clean-up and storage at -80°C prior to use.

**Methylation-specific PCR**

Methylation-specific PCR (MSP) is sensitive and specific for methylation of virtually any block of CpG sites within a CpG island. The frequency of CpG sites in CpG islands renders this technique useful and extremely sensitive for such regions. Bisulfite treated DNA was amplified with specific PCR primers (S1 Table) that distinguish methylated and unmethylated DNA. These primers amplify different sized products for DAPK1, p16, RASSF1A, PTEN, BRCA1 and p14 (for methylated and unmethylated sequences) as shown in the supplementary file (S1 Fig). PCR was carried out in a 25 μL mixture containing 10 μL of Dream Taq Master Mix (Fermentas) containing optimized buffer, 4 mM MgCl2, recombinant Taq DNA polymerase, 0.4 mM of each dNTP, 0.6 μM of each primer, and 4.0 μL of bisulfite-treated template DNA.

**RNA Extraction, polyadenylation and cDNA synthesis**

RNA from serum samples was isolated by Trizol method and stored in RNase free tubes at -70°C. The quality and integrity of the RNA was determined by the A260/280 ratio. The Poly-A tailing was carried out using Poly A Polymerase enzyme and rATP (Agilent, Cat#600036). Reverse Transcriptase and other necessary reagents for cDNA synthesis were subsequently added to convert the poly(A) tailed miRNAs into cDNA using an oligo-dT adapter primer provided with the kit. The adapter primer has a unique sequence at its 5’ end which allows amplification of cDNAs in real-time qRT-PCR reactions.

**miRNA detection by qPCR**

Relative quantitative real-time PCR (qPCR) was used to measure the expression of miRNA. qPCR was carried out on a Rotor Gene (Qiagen), using Maxima SYBR Green qPCR mastermix (Fermentas), miR-125b specific forward primer (Qiagen) (Table 1), a common universal reverse primer and snU6 as an endogenous control. 100 ng of the cDNA product amplified in the reverse transcription step above were quantified in a 20 μl reaction volume using the following amplification program: DNA Taq polymerase activation at 95°C for 5 min, followed by 40 amplification cycles of denaturation at 95°C for 10 s, annealing at 61°C for 20 s, and elongation at 72°C for 10 s. Lastly, a melting curve was generated by taking fluorescent measurements every 0.5°C for 25 s from 50°C until 95°C to ensure a single PCR product. The real-time PCR experiments were repeated atleast thrice.

The Ct values of housekeeping U6 snRNA and test mir-125b were used to calculate the delta Ct (ΔCt) values between test and reference genes in both normal healthy controls and test patients. Delta delta Ct (ΔΔCt) values between healthy controls and patients were based on difference in ΔCt values between the two sets. This was used to calculate the exponential difference based on 2−ΔΔCt. The values were normalized and expressed in terms of fold expression relative to healthy controls.

| Name | Chromosomal location | Pre-miRNA length | Sequence (mature miRNA) |
|------|----------------------|------------------|-------------------------|
| miR-125b | Chromosome 11 | 88 | 5' UCCCUGAGACCCUAACUUGUGA |

doi:10.1371/journal.pone.0153902.t001
Statistical Analysis

The correlations between the methylation levels of tumour suppressor genes and the clinical and pathological parameters were analyzed with Chi-square test or Fisher exact probability analysis. The difference of miR-125b expression levels between epithelial ovarian cancer patients and controls was examined by Student’s t-test. ROC curves were constructed using XLSTAT software. Survival analysis was performed by using Kaplan—Meier plots and log—rank (Mantel-Cox) test. Data analysis for qPCR was performed by the comparative threshold cycle (Ct) method. Each sample was examined in triplicate and the amounts of the PCR products produced were normalized to the internal controls. Gene and miRNA expression levels were obtained by relative quantification using the $2^{-\Delta\Delta Ct}$ method. Findings greater or lesser than 1 were considered to indicate overexpression or underexpression, respectively. All values were standardized relative to the normal control values, which were represented as a value of 1. The relationship of miR-125b and methylation status of TSGs was examined by Mann-Whitney U test. SPSS version 16.0 for Windows (SPSS Inc, IL, USA) and GraphPad Prism 6 for Windows (Version 6.05) were used for statistical analysis. Results were regarded as significant when $p$ was $<0.05$.

Results

Patient characteristics

Clinical-pathological features including age, histological grade and type, tumor size, menopausal status, FIGO stage, lymph node status, CA125 levels etc. are shown in Table 2. To elucidate the expression of miR-125b on the onset of cancer, epithelial ovarian cancer patients were divided into two groups, $\leq 45$ years (57.1%) and $>45$ years (42.8%). Cases were divided according to the FIGO staging of EOC and histopathological types.

Distribution of miR-125b expression pattern in cases and controls

Table 3 depicts the allocation of miR fold change expression amongst cases and controls. There was significant difference ($p<0.0001$) observed with serum miR-125b expression in epithelial ovarian cancer. One-sample t-test was used to evaluate the miRNA expression between patients and healthy controls. The level of miR expression in controls was set to one and then calculated miR expression in matched ovarian carcinoma samples. The serum expression of miR-125b was found to be 5 folds less in the controls than the corresponding epithelial ovarian cancer patient (Table 3).

Expression of miR-125b and its diagnostic potential in epithelial ovarian cancer

Real time relative quantification analysis showed more than 5 fold increase in serum miR-125b expression among epithelial ovarian cancer patients than healthy controls (Table 3). ROC curve analyses were performed to evaluate the predictive power of miR-125b for malignant ovarian cancer and illustrated in Fig 1. Relative expression of the serum miR-125b could discriminate patients with malignant ovarian cancer from healthy controls, with a power AUC of 0.728 (95% CI = 0.64–0.81) at a sensitivity of 62.3% and specificity of 77.1% from a cut-off score of 3.76.

miR-125b upregulation in relation to clinicopathological features

Table 2 depicts the correlation between miR-125b expression and clinicopathological characteristics of epithelial ovarian cancer patients. Around 64% of patients of $>45$ years of age
Table 2. Association between miR-125b expression and clinicopathological characteristics in epithelial ovarian cancer.

| Parameter            | Number n(%)   | miR-125b ExpressionHigh (n)(%) | p-value |
|----------------------|---------------|-------------------------------|---------|
| **Age (years)**      |               |                               |         |
| ≤45                  | 40 (57.1)     | 17 (42.5)                     | 0.13    |
| >45                  | 30 (42.8)     | 19 (63.3)                     |         |
| **Histological grade** |          |                               |         |
| Well                 | 25 (35.7)     | 12 (48.0)                     | 0.04    |
| Moderate             | 26 (37.1)     | 18 (69.2)                     |         |
| Poor                 | 19 (27.1)     | 6 (31.5)                      |         |
| **Histological type** |            |                               |         |
| Mucinous             | 36 (51.4)     | 18 (50.0)                     | 0.31    |
| Serous               | 17 (24.2)     | 11 (64.7)                     |         |
| Papillary            | 8 (11.4)      | 2 (25.0)                      |         |
| Others               | 9             | 5 (55.5)                      |         |
| **Tumor size**       |               |                               |         |
| <10 cm³              | 5 (7.1)       | 4 (80.0)                      | 0.22    |
| 10–50 cm³            | 7 (10.0)      | 5 (71.4)                      |         |
| 50–200 cm³           | 14 (20.0)     | 9 (64.2)                      |         |
| 200–500 cm³          | 17 (24.2)     | 7 (41.1)                      |         |
| >500 cm³             | 27 (38.5)     | 11 (40.7)                     |         |
| **FIGO stage**       |               |                               |         |
| I                    | 23 (32.8)     | 23 (100.0)                    | <0.0001 |
| II                   | 10 (14.2)     | 10 (100.0)                    |         |
| III                  | 19 (27.1)     | 2 (10.5)                      |         |
| IV                   | 18 (25.7)     | 1 (5.5)                       |         |
| **Distant metastasis** |         |                               |         |
| Absent               | 52 (74.2)     | 35 (67.3)                     | 0.002   |
| Present              | 18 (25.7)     | 1 (5.0)                       |         |
| **Lymph node status** |              |                               |         |
| Absent               | 51 (72.8)     | 33 (64.7)                     | 0.001   |
| Present              | 19 (27.1)     | 3 (15.7)                      |         |
| **Menopause**        |               |                               |         |
| Pre                  | 39 (55.7)     | 17 (43.5)                     | 0.21    |
| Post                 | 31 (44.2)     | 19 (61.2)                     |         |
| **Nulliparity**      |               |                               |         |
| Absent               | 51 (44.2)     | 30 (58.8)                     | 0.07    |
| Present              | 19 (27.1)     | 6 (31.5)                      |         |
| **Serum CA125 (U/ml)** |            |                               |         |
| ≤35                  | 9 (11.4)      | 5 (55.5)                      | 0.92    |
| >35                  | 61 (88.5)     | 31 (50.8)                     |         |
| **Hemoglobin (gm/dL)** |            |                               |         |
| ≤12                  | 59 (84.2)     | 30 (50.8)                     | 0.92    |
| >12                  | 11 (15.7)     | 6 (54.5)                      |         |

doi:10.1371/journal.pone.0153902.t002

Table 3. Distribution of fold change expression pattern of miR-125b in EOC patients.

| miRNA    | Number of samples (N) | Mean fold change expression ± SD | 95% C.I   | p-value       |
|----------|-----------------------|----------------------------------|-----------|--------------|
| miR-125b | 70                    | 5.25±1.04                        | 0.845–1.66| <0.0001      |

doi:10.1371/journal.pone.0153902.t003
showed high expression of miR-125b. Almost 70% patients having moderate grade tumour exhibited increased expression of miR-125b apart from 48% patients with well differentiated tumour and 32% poorly differentiated tumour. Elevated expression of miR-125b was seen in around 65% serous adenocarcinoma patients and about 50% patients with mucinous adenocarcinoma. When correlated with tumour size, high expression of miR-125b was observed when tumour was at its initial stage i.e. \(<10\text{cm}^3\). Moreover, all patients in the early stage (stage I and II) showed high expression of miR-125b. Patients having no metastasis ie, involving those patients in the early stage, summed up almost 67% of patients with increased expression of miR-125b as compared to patients (5%) with metastatic disease. Similarly, 65% patients with no lymph node metastasis showed higher expression of miR-125b. Menopausal status, nulliparity, serum CA125 levels and haemoglobin (Hb) concentration did not associate significantly with the expression of miR-125b. Fig 2 demonstrates the significant relationship with respect to stage, lymph node metastasis and distant metastasis status with the expression of miR-125b in epithelial ovarian cancer patients.

**miR-125b with respect to stage of epithelial ovarian cancer.** A lucid demarcation was observed with respect to the expression of miR-125b and the FIGO stages in epithelial ovarian cancer. All patients in Stage I and stage II presented higher expression of miR-125b while patients in stage III and IV counted merely 10% and 5% of patients with increased expression respectively (Fig 2A).

**miR-125b is upregulated in non metastasized tumours.** A statistically significant (p = 0.002) correlation was observed between the metastasis status of epithelial ovarian cancer patients and miR-125b expression. Expression of miR-125b was found to be specifically increased in patients with no metastasis (Fig 2B).
miR-125b is upregulated in patients with no lymph node metastasis. As with distant metastasis, patients with no lymph node metastasis showed a statistically significant (p = 0.001) correlation with the expression of miR-125b (Fig 2C).

Expression of miR-125b and its prognostic potential in epithelial ovarian cancer

miR-125b was analyzed for its disease progression, prognostic significance and survival outcome in EOC. miR-125b was evaluated for disease progression by the association of its expression with the FIGO stages and various other clinicopathological parameters of epithelial ovarian cancer. The prognostic significance was elucidated by ROC curves. To use ROC curve analysis, the clinical and tumor characteristics were made binary and therefore dichotomized. Stage was dichotomized as early (I+II) or late (III+IV), tumor grade as low (G1+G2) or high (G3), node involvement as no lymph node involvement or any lymph node involvement, distant metastasis as present or absent, survival as death due to epithelial ovarian cancer or other (censored/alive).

The expression of miR-125b and histological grade yielded a significant AUC of 0.676 (95% CI: 0.558–0.793) with a sensitivity of 66.7% and specificity of 62.6% from an optimal cut-off value of 3.91 (Fig 3A) (Table 4). ROC curve for distant metastasis yielded an AUC of 0.891 (95% CI: 0.838–0.944) with a sensitivity and specificity of 94.1% and 70.5% respectively at an optimal cut-off value of 4.34 (Fig 3B). An AUC of 0.773 (95% CI: 0.658–0.887) was obtained in ROC curve with respect to lymph node metastasis and at an optimal cut-off value of 5.85, the sensitivity was 73.7% and specificity was 80.8% (Fig 3C). ROC curve for survival yielded an AUC of 0.660 (95% CI: 0.564–0.756) with a sensitivity of 64.3% and specificity of 67.0% at an optimal cut-off score of 3.91 (Fig 3D).

The survival analysis was done by Kaplan-Meier curve and log-rank test (Fig 4A). There was no significant association found between the miR-125b expression and overall survival of patients with 1 fold expression of miR-125b. However, when histological subgroups were estimated for survival separately, it was found that patients with mucinous histotypes had a survival time of 16 months whereas, patients with serous histotypes exhibited a survival time of 9 months (Fig 4B).
Expression of miR-125b in association with promoter hypermethylation of tumour suppressor genes

The relative expression of miR-125b was assessed in relation to the promoter hypermethylation of well known tumour suppressor genes—DAPK1, p16, RASSF1A, PTEN, BRCA1 and p14.

Table 4. AUC for ROC curve corresponding to the diagnostic value of miR-125b in EOC.

| Parameter            | AUC   | Standard Error | 95% C.I.     |
|----------------------|-------|----------------|--------------|
| Histological grade   | 0.676 | 0.060          | 0.558–0.793  |
| Distant metastasis   | 0.891 | 0.027          | 0.838–0.944  |
| Lymph node           | 0.773 | 0.059          | 0.658–0.887  |
| Survival             | 0.660 | 0.049          | 0.564–0.756  |

doi:10.1371/journal.pone.0153902.t004
Out of these, RASSF1A and PTEN genes showed a statistically significant correlation between the aberrant hypermethylation of their promoter and the relative expression of miR-125b in epithelial ovarian cancer patients. Patients with RASSF1A promoter hypermethylation demonstrated downregulation of miR-125b expression (p = 0.005) (Fig 5). Similarly, patients with PTEN promoter hypermethylation showed downregulation of miR-125b expression (p = 0.01). No other tumour suppressor gene exhibited a statistically significant association with miR-125b expression.

Discussion

The development of epithelial ovarian carcinogenesis is a multistep procedure entailing the dysregulation of oncogenes and tumor suppressor genes. Contemporary studies have reported that microRNA-associated transcriptionally regulated gene expression plays a crucial role in the initiation, development and progression of epithelial ovarian cancer, by keeping a regulatory check on the cell proliferation, cell cycle, apoptosis, and metastasis. miR-125b has been reported to be involved in multiple cancers[12]. miR-125b functions either as an oncogene or tumor suppressor gene. It is upregulated and displays oncogenic potential in some cancers as it triggers cell division, while hampering apoptosis. On the other hand, it is overtly downregulated in various other cancers. Our understanding with respect to the contradictory roles of miR-125b in plethora of cancers is still limited. One aspect of our aim was to explore the aberrant expression of miR-125b in epithelial ovarian cancer in relation to the clinicopathological attributes. The other aspect was to test the expression of miR-125b with reference to the anomalously methylated TSGs in order to vividly conclude their possible role in either regulating or being regulated by miR-125b.

miR-125b is thought to target the hallmarks of cancer in one way or the other, regulating multiple genes involved in the pathway, leading to the development of the cancer phenotype. Aberrant DNA methylation has a critical outcome on epithelial ovarian cancer initiation and progression. Several investigators have looked for the hypermethylation of the miRNA promoter in different cancers as a reason for the inactivation of that particular miRNA and highlighting the putative role of epigenetic disruption in producing the aberrant patterns of expression of miRNAs in cancer cells[13]. Several lines of evidence support the idea that dysregulation of miRNA can lead to aberrant DNA methylation in cancer and that miRNAs
able to regulate DNMT genes are reportedly downregulated in cancer\cite{14,15}. miRNAs which act as tumour suppressors have been found to be methylated in tumour cells indicating the significance the studying the two forces together- epigenetics and miRNAs\cite{16}. Also, the DNA methylation profile of tumors can be used as a signature to define tumor type, clinical prognosis and treatment response\cite{17,18}. miRNAs transcribed from CpG islands undergo DNA methylation-associated repression with a similar chromatin context to coding genes, such as binding of the transcriptional repressor methyl-CpG-binding domain proteins \cite{19,20}. Such genetic unmasking studies have paved way in identifying the mechanisms responsible for causing the cancer havoc at the molecular level. Based on similar lines, we selected a panel of tumour suppressor genes, which are known to be susceptible in epithelial ovarian cancer to investigate whether their aberrant methylation directly or indirectly affects the expression of miR-125b which in turn leads to the development of cancer. Of the studied tumour suppressor genes, RASSF1A and PTEN genes emerged as likely candidates which might be playing a crucial role in modulating the expression of miR-125b. Poliseno et al. have demonstrated the role of PTEN transcripts in modulating miRNA targeting by

---

Fig 5. Association of miR-125b expression with the promoter hypermethylation of a panel of tumour suppressor genes. (A)DAPK1 (B) p16 (C) RASSF1A (D) PTEN (E) BRCA1 (F) p14. Positive and negative depicts the presence or absence of promoter hypermethylation of the specified tumour suppressor gene respectively.

doi:10.1371/journal.pone.0153902.g005
examining PTENP1 levels[21]. The identification and validation of numerous PTEN-targeting microRNAs indicates that post-transcriptional regulation plays a central role in determining PTEN abundance in cancer cells[22–25]. Cells are highly sensitive to even slight decrease in PTEN levels, highlighting the importance of microRNA-mediated PTEN regulation in cancer[26]. RASSF1A is a tumor suppressor that is a negative regulator in the RAS–MAPK pathway and has reduced expression in various cancers. It has been proposed that RASSF1A participates in cell proliferation and apoptosis by regulating the MAPK pathway and has effects on carcinogenesis[27]. Another study by Banno et al. reported that reduced expression of RASSF1A gene occurs by hypermethylation or suppression of gene expression by miRNAs. Expression of the miRNA itself may be increased or decreased by promoter methylation, based on differences between normal and cancerous cells[28]. Hence our study has extrapolated these results and might give a new direction to examine the expression of miR-125b in a new dimension.

Recent technological advancements have aided the detection of miRNAs at optimum sensitivity and specificity. Circulating miRNAs are emerging as promising diagnostic biomarkers for cancer though their usefulness for detecting early neoplasms still remains unclear. miR-125b has been shown to target multiple genes which are more or less relevant in the formation of tumour in different cell types. miR-125b acts as classical oncogene in a variety of tumours where its overexpression may lead to the suppression of a tumour suppressor gene or block its apoptotic machinery. This is further supported by the finding that miR-125b expression levels are correlated with reduced survival rates[29,30]. A recent study by Yamada et al. has also reported an elevated level of miR-125b in colorectal cancer. They identified miR-125b as an early detection biomarker in colorectal cancer owing to the considerable AUC (0.806) in the ROC curve[31]. Giray et al. found an upregulation of miR-125b expression in hepatocellular carcinoma and suggested that it could serve as a novel, non invasive biomarker in this cancer[32]. Jiang and colleagues also showed an upregulation of miR-125b in vivo and in vitro in endometrial carcinoma[33]. In addition, overexpression of miR-125b has been investigated in several cancers such as pancreatic cancer[34], prostate cancer[35], breast cancer[36,37], lung cancer[38], glioblastoma[39], oligodendrogial cancer[7] amongst other cancers. Conversely, miR-125b has been shown to be downregulated in a number of tumours such as bladder cancer[40], esophageal cancer[41], osteosarcoma[42], prostate cancer[43], liver cancer[44], breast cancer[45], non-small cell lung cancer (NSCLC)[46], breast cancer[47], gastric cancer[48], glioblastoma[49] etc. In ovarian cancer, contradictory studies on miR-125b have made it a necessity to survey its role profoundly. Lee et al. reported a downregulation of miR-125b in ovarian cancer tissue and cell lines compared to healthy controls[50]. Luo and colleagues have also recently reported a downregulation of miR-125b in ovarian cancer tissue and cell lines[51]. Gadducci et al. also observed similar results[52]. He et al. suggested a novel therapeutic approach using miR-125b mimic in the treatment of ovarian cancer[53]. Guan et al. reported that overexpression of miR-125b resulted in the inhibition of ovarian cancer cell proliferation[54]. On the other hand, Kong and colleagues reported an upregulation of miR-125 in ovarian cancer and suggested that up-regulation of miR-125b expression contributes to cisplatin resistance through suppression of Bak1 expression[55]. Diverse expression of miR-125b was reported in drug-resistant ovarian cancer cell lines by Sorrentino et al[56].

The association of miR-125b with various clinicopathological features reflect that miR-125b may function as an early biomarker for ovarian cancer. The elevated expression in the early stages as compared to the advanced stage speaks volumes of its significance in indicating the onset of the disease. The expression of miR-125b in relation to the distant metastasis status and lymph node status suggest its possible potential in the early diagnosis of ovarian cancer.
Conclusion

Increasing number of studies have shown that miR-125b plays a crucial role in diverse cellular processes and many diseases especially carcinomas. It is noteworthy that the functions of miR-125b are controversial in different types of cancers. Hence, the controversial properties of miR-125b in various tumors suggest that miR-125b have distinct functions in cancer pathogenesis and progression, while the underlying mechanisms on different cell context need further validation. The advances that miR-125b holds in clinical applications need a closer look for future treatment of cancer.

Supporting Information

S1 Fig. Electrophoretic band pattern for hypermethylation for a panel of tumor suppressor genes visualized on 2% agarose gel under UV transillumination.
(EPS)

S1 Table. Sequence of primers with annealing temperatures and band size used for MS-PCR.
(RTF)

Acknowledgments

We are grateful to Dr. V Sreenivas for his help and cooperation in the statistical analysis of this manuscript.

Author Contributions

Conceived and designed the experiments: MZ RM AS. Performed the experiments: MZ. Analyzed the data: MZ IK. Contributed reagents/materials/analysis tools: GG PCR AS RM. Wrote the paper: MZ IK RM. Helped in recruiting the subjects: GG PCR.

References

1. Kinose Y, Sawada K, Nakamura K, Kimura T, Kinose Y, Sawada K, et al. The Role of MicroRNAs in Ovarian Cancer, The Role of MicroRNAs in Ovarian Cancer. BioMed Res Int BioMed Res Int. 2014 Sep 10; 2014, 2014:e249393.
2. Catto JWF, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011 May; 59(5):671–81. doi:10.1016/j.eururo.2011.01.044 PMID: 21296484
3. Heinzelmann J, Unrein A, Wickmann U, Baumgart S, Stapf M, Szendroi A, et al. MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases. Ann Surg Oncol. 2014 Mar; 21(3):1046–54. doi:10.1245/s10434-013-3361-3 PMID: 24242678
4. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010 Jun; 10(6):389–402. doi: 10.1038/nrc2867 PMID: 20495573
5. Vargas Romero P, Cialli S, Palermo R, De Blasio C, Checquolo S, Bellavia D, et al. The deregulated expression of miR-125b in acute myeloid leukemia is dependent on the transcription factor C/EBPa. Leukemia. 2015 Dec; 29(12):2442–5. doi: 10.1038/leu.2015.117 PMID: 25982911
6. Ribeiro J, Marinho-Dias J, Monteiro P, Loureiro J, Baldaque I, Medeiros R, et al. miR-34a and miR-125b Expression in HPV Infection and Cervical Cancer Development. BioMed Res Int. 2015; 2015:304584. doi: 10.1155/2015/304584 PMID: 26180794
7. NELSON PT, BALDWIN DA, KLOOSTERMAN WP, KAUPPINEN S, PLASTERK RHA, MOURELATOS Z. RAKE and LNA-ISH reveal microRNA expression and localization in archival human brain. RNA. 2006 Feb; 12(2):187–91. PMID: 16373485
8. Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, et al. Expression of microRNAs and Protein-coding Genes Associated with Perineural Invasion in Prostate Cancer. The Prostate. 2008 Aug 1; 68(11):1152–64. doi: 10.1002/pros.20786 PMID: 18459106
9. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem. 2007 Jan 12; 282(2):1479–86. PMID: 17110380
10. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res Off J Am Assoc Cancer Res. 2011 May 1; 17(9):2725–33.
11. Chen H, Xu Z. Hypermethylation-Associated Silencing of miR-125a and miR-125b: A Potential Marker in Colorectal Cancer. Dis Markers [Internet]. 2015 [cited 2016 Feb 2];2015. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674596/
12. Banzhaf-Strathmann J, Edbauer D. Good guy or bad guy: the opposing roles of microRNA 125b in cancer. Cell Commun Signal CCS. 2014; 12:30. doi:10.1186/1478-811X-12-30 PMID: 24774301
13. Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012 Dec; 6(6):567–78. doi: 10.1016/j.molonc.2012.07.007 PMID: 22902148
14. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Sjoblom T, et al. The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006 Mar 7; 103(10):3687–92. PMID: 16505370
15. Suzuki H, Maruyama R, Yamamoto E, Kai M. DNA methylation and microRNA dysregulation in cancer. Mol Oncol. 2012 Dec; 6(6):567–78. doi: 10.1016/j.molonc.2012.07.007 PMID: 22902148
16. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007 Oct 2; 104(40):15805–10. PMID: 17890317
17. Lujambio A, Esteller M. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle Georget Tex. 2007 Jun 15; 6(12):1455–9. doi:10.4161/epi.5.7.13055 PMID: 20716963
18. Urdinguio RG, Fernandez AF, Lopez-Nieva P, Rossi S, Huertas D, Marín P, et al. MicroRNA-125b is an independent prognostic factor in human colorectal cancer. Int J Oncol. 2011 May; 38(5):1437–43. doi: 10.3892/ijo.2011.969 PMID: 21399871
30. Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol. 2012 Dec; 138(12):2045–50. doi: 10.1007/s00432-012-1285-0. PMID: 22806310

31. Yamada A, Horimatsu T, Okugawa Y, Nishida N, Honjo H, Ida H, et al. Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. Clin Cancer Res Off J Am Assoc Cancer Res. 2015 Sep 15; 21(18):4234–42.

32. Giray BG, Emekdas G, Tezcan S, Ulger M, Serin MS, Sezgin O, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. Mol Biol Rep. 2014 Jul; 41(7):4513–9. doi: 10.1007/s11033-014-3322-3. PMID: 24595450

33. Jiang F, Liu T, He Y, Yan Q, Chen X, Wang H, et al. MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer. 2011; 11:425. doi: 10.1186/1471-2407-11-425. PMID: 21970405

34. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNA expression patterns in differentiating pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007 May 2; 297(17):1901–8. PMID: 17473300

35. Shi X-B, Xue L, Yang J, Ma A-H, Zhao J, Xu M, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19983–8. PMID: 18056640

36. Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, et al. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res BCR. 2015; 17:13. doi: 10.1186/s13058-015-0515-1. PMID: 25633049

37. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, et al. Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer. PLoS ONE. 2012 Apr 16; 7(4):e34210. doi: 10.1371/journal.pone.0034210. PMID: 22523546

38. Wang X, Zhang Y, Fu Y, Zhang J, Yin L, Pu Y, et al. MicroRNA-125b may function as an oncogene in lung cancer cells. Mol Med Rep. 2015 May; 11(5):3880–7. doi: 10.3892/mmr.2014.3142. PMID: 25573191

39. Wu N, Lin X, Zhao X, Zheng L, Xiao L, Liu J, et al. MiR-125b acts as an oncogene in glioblastoma cells and inhibits cell apoptosis through p53 and p38MAPK-independent pathways. Br J Cancer. 2013 Nov 26; 109(11):2853–63. doi: 10.1038/bjc.2013.672. PMID: 24169356

40. Zhao X, He W, Li J, Huang S, Wan X, Luo H, et al. MiRNA-125b inhibits proliferation and migration by targeting SphK1 in bladder cancer. Am J Transl Res. 2015; 7(11):2346–54. PMID: 26807182

41. Zang B, Huang G, Wang X, Zheng S. HPV-16 E6 promotes cell growth of esophageal cancer via down-regulation of miR-125b and activation of Wnt/β-catenin signaling pathway. Int J Clin Exp Pathol. 2015; 8(10):13687–94. PMID: 26722596

42. Wang F, Yu D, Liu Z, Wang R, Xu Y, Cui H, et al. MiR-125b Functions as a Tumor Suppressor and Enhances Chemosensitivity to Cisplatin in Osteosarcoma. Technol Cancer Res Treat. 2016 Jan 6; 15(1):82. doi: 10.3892/ijt.2015.3. PMID: 26544868

43. Budd WT, Seashols-Williams SJ, Clark GC, Weaver D, Calvert V, Petricoin E, et al. Dual Action of miR-125b, as a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis. PloS One. 2015; 10(11):e0142373. doi: 10.1371/journal.pone.0142373. PMID: 26544868

44. Zhou J-N, Zeng Q, Wang H-Y, Zhang B, Li S-T, Nan X, et al. MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4. Hepatol Baltim Md. 2015 Sep; 62(3):801–15.

45. Xie X, Hu Y, Xu L, Fu Y, Tu J, Zhao H, et al. The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer. Tumour Biol Int J Oncodevelopmental Biol Med. 2015 Aug; 36(9):7185–94.

46. Wang M, Zhu X, Sha Z, Li N, Li D, Chen L. High expression of kinesin light chain-2, a novel target of miR-125b, is associated with poor clinical outcome of elderly non-small-cell lung cancer patients. Br J Cancer. 2015 Mar 3; 112(5):879–82. doi: 10.1038/bjc.2015.3. PMID: 25668010

47. Yang Q, Wang Y, Lu X, Zhao Z, Zhu L, Chen S, et al. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells. Oncotarget. 2015 Feb 20; 6(5):3268–79. PMID: 25605244

48. Wu S, Liu F, Xie L, Peng Y, Lv X, Zhu Y, et al. miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer, miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer. BioMed Res Int BioMed Res Int. 2015 Oct 4; 2015:e365273.

49. Wan Y, Sun G, Wang Z, Guo J, Shi L. miR-125b promotes cell proliferation by directly targeting Lin28 in glioblastoma stem cells with low expression levels of miR-125b. Neuroreport. 2014 Mar 26; 25(5):289–96. PMID: 24356103
50. Lee M, Kim EJ, Jeon MJ. MicroRNAs 125a and 125b inhibit ovarian cancer cells through post-transcriptional inactivation of EIF4EBP1. Oncotarget. 2015 Dec 5;

51. Luo S, Wang J, Ma Y, Yao Z, Pan H. PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-125b. Biochem Biophys Res Commun. 2015 Jun 26; 462(2):85–90. doi: 10.1016/j.bbrc.2015.04.023 PMID: 25944662

52. Gadducci A, Sergiampietri C, Lanfredini N, Guiggi I. Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2014 Apr; 30(4):266–71.

53. He J, Jing Y, Li W, Qian X, Xu Q, Li F-S, et al. Roles and mechanism of miR-199a and miR-125b in tumor angiogenesis. PloS One. 2013; 8(2):e56647. doi: 10.1371/journal.pone.0056647 PMID: 23437196

54. Guan Y, Yao H, Zheng Z, Qiu G, Sun K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer J Int Cancer. 2011 May 15; 128(10):2274–83.

55. Kong F, Sun C, Wang Z, Han L, Wang D, Lu Y, et al. miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1. J Huazhong Univ Sci Technol Med Sci Hua Zhong Ke Ji Xue Xue Bao Yi Xue Ying Wen Ban Huazhong Keji Daxue Xuebao Yixue Yingde- wen Ban. 2011 Aug; 31(4):543–9.

56. Sorrentino A, Liu C-G, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008 Dec; 111(3):478–86. doi: 10.1016/j.ygyno.2008.08.017 PMID: 18823650